Author

M. Periyasamy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

S. Ali· 3 shared A. Belfiore· 1 shared A. J. Nicholls· 1 shared A. Lima· 1 shared A. Macdonald· 1 shared A. S. Mason· 1 shared A. Singh· 1 shared B. Kruspig· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

S. Ali

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma

S. Laing, B. Kruspig, R. Shaw, L. Officer-Jones, S. Edwards, D. McKinven, Y.-C. Hsieh, I. Powley, N. Brady, R. Pennie, R. Kwan, A. Lima, S. Myrta, M. Periyasamy, I. C. Dye, , D. J. Murphy

The paper investigates how ERBB signaling contributes to immune evasion in KRAS-driven lung adenocarcinoma using a novel mouse model and finds that transient ERBB blockade can restore immune surveillance when combined with PD1 blockade.

bioRxiv · Jul 24, 2023 · PreprintCancer Biology

BK polyomavirus (BKPyV) is a risk factor for bladder cancer through induction of APOBEC3-mediated genomic damage

S. C. Baker, A. S. Mason, R. G. Slip, K. T. Skinner, A. Macdonald, O. Masood, R. S. Harris, T. R. Fenton, M. Periyasamy, S. Ali, J. Southgate

This study shows BKPyV infection increases APOBEC3-mediated genomic damage in urothelial cells, contributing to bladder cancer risk in immunocompromised individuals.

bioRxiv · May 13, 2021Cancer Biology

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

C. Gemma, C. Lai, A. Singh, A. Belfiore, N. Portman, H. Z. Milioli, M. Periyasamy, S. Abuelmaaty, A. J. Nicholls, C. Davies, N. R. Patel, G. Simmons, H. Fan, V. Nguyen, L. Magnani, , S. Ali

This study identifies VGLL1 as a driver of resistance to endocrine therapy in ER+ breast cancer and shows that targeting VGLL1/TEAD interaction can inhibit resistant cell growth.

bioRxiv · Nov 29, 2020Cancer Biology